Is there an official retatrutide dose?
No. This is the most important thing to know, so let us say it plainly first. There is no official retatrutide dose. There is no approved chart you are supposed to follow.
Retatrutide is what scientists call investigational. That is a careful word that just means: it is still being tested, and it has not been approved yet. The FDA — the part of the US government that checks whether a medicine is safe and actually works — has not approved retatrutide for anyone. Because of that, the only place it is used at all is inside clinical trials (the controlled studies where researchers test a new medicine on volunteers).
So if you came here looking for "the dose," the honest answer is that one does not officially exist. What does exist is information about the doses researchers chose to test in those trials. That is what the rest of this page is — trial information, not a recommendation, and not instructions for taking anything.
Why does the difference matter so much? Because an "approved dose" is not just a number someone picked — it is a conclusion. It is what regulators settle on after large studies show that a specific amount does more good than harm for a defined group of people. Retatrutide has not reached that conclusion yet. So describing the trial doses is fair game; presenting any of them as "the amount to take" would be inventing an answer the science has not produced.
What doses were used in the clinical trials?
In the main study of retatrutide for weight — a Phase 2 trial, meaning an early, medium-sized study published in 2023 — researchers tested four dose levels. They were 1 milligram, 4 milligrams, 8 milligrams, and 12 milligrams, each given as one injection once a week. A milligram (mg) is just a small unit of weight, the way the amount of medicine is measured.
It is worth being clear about why those numbers exist. Researchers picked them to study the medicine — to see how the body responds as the dose goes up. They were assigned by a trial protocol, the strict written plan a study follows. They were not picked as a "right amount" for any one person, and they are not a starting point anyone should copy on their own.
In that trial, the highest level studied, 12 mg a week, produced the largest average weight change: people in that group lost about 24% of their body weight on average after 48 weeks (just under a year). That is a striking result for an early study, but "striking in a trial" and "settled medical fact" are not the same thing, which is the next piece to understand.
There is one more reason researchers test a ladder of doses rather than a single number. Comparing 1, 4, 8, and 12 mg side by side shows how the body responds as the amount goes up — whether benefits keep climbing, where side effects start to outweigh them, and how much is "enough." That is the actual job of an early trial: not to publish a dose for the public to follow, but to gather the evidence regulators will later use to decide whether any dose should be approved at all.
Were the same doses studied in the diabetes trials?
Retatrutide was not only tested for weight. A separate early study looked at adults with type 2 diabetes — a condition where blood sugar runs too high. Knowing this matters here, because that study tested a slightly different set of dose levels, which is a good reminder that "the doses" depend on which study you are reading.
In that diabetes trial, researchers studied weekly doses of 0.5 mg, 4 mg, 8 mg, and 12 mg. Notice the lowest rung — 0.5 mg — sits below the 1 mg used in the obesity study. For the 4 mg and 8 mg levels, the researchers even tried two different step-up plans (two ways of climbing to the same maintenance dose) to see which the body tolerated best.
The takeaway is not a number to copy. It is that even within the research itself, the dose levels and the way people worked up to them were not fixed — they were choices a study protocol made, on purpose, to learn something. That is the opposite of a settled, one-size dose. It is researchers still mapping out how the medicine behaves.
| Phase 2 trial | Weekly doses studied | Notes |
|---|---|---|
| Obesity (Jastreboff 2023) | 1, 4, 8, 12 mg | Titrated up from a 2 mg or 4 mg start |
| Type 2 diabetes (Rosenstock 2023) | 0.5, 4, 8, 12 mg | Two step-up plans tested at 4 and 8 mg |
| Fatty liver / MASLD (Sanyal 2024) | 1, 4, 8, 12 mg | Once-weekly subcutaneous over 48 weeks |
Why did the trials raise the dose gradually?
Here is a detail that surprises people: in the trial, people did not start on the high dose. The researchers worked up to it slowly. Doctors call this titration — a long word that simply means starting low and stepping up bit by bit over time.
Why bother? Because of the stomach. Medicines in this family can upset the gut, especially at the start — think nausea (feeling sick), or an unsettled stomach. The trial found that beginning at a lower 2 mg dose, before climbing higher, cut down on those early stomach problems. Starting gently gives the body time to get used to the medicine.
A simple way to picture it is easing into a cold pool instead of jumping straight in. Same water, much gentler experience. That is the whole idea behind raising the dose gradually — and again, the pace and the steps are something a trial protocol or a doctor controls, not something to improvise.
Why is it given once a week instead of every day?
One reason a dosing schedule sounds simple — one injection a week — comes down to chemistry, not preference. Retatrutide has a long half-life. Half-life is the time the body takes to clear half of a drug. For retatrutide, researchers reported a half-life of about 6 days.
Six days is long. It means that almost a week after a dose, roughly half of it is still in the body. Because it lingers that long, a single weekly injection keeps a meaningful amount around until the next one is due. In the early discovery work, scientists noted the medicine's pharmacokinetics — how it moves through and leaves the body — supported once-weekly dosing, with effects from a single dose lasting for weeks.
This is worth knowing precisely because it shapes what a real schedule would look like, if one is ever approved: weekly, not daily. But "once a week" describes how often a dose is given in the studies — it says nothing about how big a dose should be for any individual. That, again, is not something this page or any chart can answer.
Why isn't there an approved dose chart yet?
A medicine has to clear several rounds of testing before it can be approved, and each round is bigger and more careful than the last. The 2023 results came from a Phase 2 trial — an early, medium-sized study. It was promising, but early studies are not the final word.
The next and larger stage, called Phase 3, is still going on. (The retatrutide Phase 3 program is named TRIUMPH.) Until those bigger studies finish and regulators review them, nothing is settled — not whether the medicine will be approved, and not what an official dose would be.
That is exactly why there is no approved dose chart: the work that would create one has not finished. So any chart you see online claiming to be "the retatrutide dosing schedule" is presenting trial information, or guesswork, as if it were official guidance. It is not.
Why do "retatrutide dosage charts" exist online at all?
If there is no official dose, you might wonder why the internet is full of neat-looking retatrutide "charts" with weeks and milligrams laid out in a grid. The honest answer is that most of them take the numbers from the published trials — the 1, 4, 8, and 12 mg levels, and the slow step-up — and reformat them to look like a schedule you are meant to follow.
Reformatting trial data as a how-to is where it goes wrong. In the studies, those numbers came packaged with things a chart leaves out: medical screening before anyone started, doctors watching for side effects, blood tests, and a protocol that could pause or slow the climb for any individual. Strip all that away and you are left with bare numbers pulled out of their safety context.
There is a second problem worth naming plainly. Because retatrutide is not approved, it is not sold through pharmacies. Anything offered online under that name sits entirely outside the supervised trial setting, and there is no independent guarantee of what is actually in it or how strong it is. A chart cannot fix that. So treat any online "dosing schedule" as a repackaging of early research, not as instructions — and bring real questions to a licensed clinician instead.
This is not a dosing recommendation
To be completely clear: nothing on this page is medical advice, and nothing here tells anyone how much retatrutide to take. We have described the doses researchers chose for their studies. That is background information about the science — not a plan for any individual.
Choosing a dose of an investigational medicine is a medical decision, and a serious one. It belongs to a licensed doctor, working inside an approved clinical trial with its written protocol — people who can weigh someone's health history, watch for side effects, and adjust as needed. It is not something to figure out from an article, a chart, or a forum post.
And one more honest point: because retatrutide is only used in trials right now, it is not something you can simply buy and use. Anything sold online under that name sits entirely outside that controlled, supervised setting. If a GLP-1-type medicine is something you are curious about, the right next step is a conversation with a licensed clinician, who can talk through what is actually approved and available today.
It is also worth being clear about why a number that looks safe in a study can be risky on your own. In a trial, the dose, the schedule, and the person are matched carefully — a doctor confirms there are no conditions that make the medicine a bad idea, checks bloodwork, and stays involved if something changes. The same milligram amount, taken without any of that, is a completely different situation. The number on a chart is the easy part to copy; the medical judgment around it is the part that actually keeps people safe, and it cannot be copied from a webpage.
Keeping track of it all with PeptidePanel
If a doctor is overseeing a treatment plan — for any medicine — there is a lot of day-to-day detail to keep straight: when the next dose is due, how weight is trending, and the lab numbers the doctor watches over time. That is easy to lose track of in your head.
PeptidePanel is a simple tracking tool for exactly that. It records the plan a doctor set, charts the results, and sends a reminder when something is due. It does not sell, supply, prescribe, or recommend any medicine — and it does not provide doses. It is just the notebook that keeps a doctor's plan organized, whatever that plan happens to be. The doses, the timing, and the decisions stay where they belong: between a person and their clinician.